Multiple myeloma (MM) is an incurable neoplastic hematologic disorder characterized by the malignant proliferation of monoclonal plasma cells, mainly in the bone marrow. Multiple risk factors, such as lipid metabolism, obesity, and age, are associated with the development of MM. MM is the second most common hematological malignancy, comprising 13–15% of all blood cancers. MM is associated with end-organ damage including lytic bone lesions, anemia, immunodeficiency, and decreased renal function.
During the last 20 years, developments in disease management, including combination of various targeting agents with the classical chemotherapeutic regimens have changed the prognosis and improved the lifespan of patients with MM. However, due to the high heterogeneity and drug resistance of MM, the prognosis of MM is still poor. Despite the progress in understanding the molecular pathogenesis of MM, many vital questions remain unanswered.
This Research Topic will focus on advances in the understanding of the molecular mechanisms behind MM. We aim to elucidate the molecular mechanisms of MM in order to improve diagnosis, therapy and survival for patients. We welcome papers on the following topics:
- Molecular mechanisms of multiple myeloma
- Genetic and Epigenetic mechanisms of multiple myeloma
- The role of blood lipoproteins in the pathogenesis of MM
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Multiple myeloma (MM) is an incurable neoplastic hematologic disorder characterized by the malignant proliferation of monoclonal plasma cells, mainly in the bone marrow. Multiple risk factors, such as lipid metabolism, obesity, and age, are associated with the development of MM. MM is the second most common hematological malignancy, comprising 13–15% of all blood cancers. MM is associated with end-organ damage including lytic bone lesions, anemia, immunodeficiency, and decreased renal function.
During the last 20 years, developments in disease management, including combination of various targeting agents with the classical chemotherapeutic regimens have changed the prognosis and improved the lifespan of patients with MM. However, due to the high heterogeneity and drug resistance of MM, the prognosis of MM is still poor. Despite the progress in understanding the molecular pathogenesis of MM, many vital questions remain unanswered.
This Research Topic will focus on advances in the understanding of the molecular mechanisms behind MM. We aim to elucidate the molecular mechanisms of MM in order to improve diagnosis, therapy and survival for patients. We welcome papers on the following topics:
- Molecular mechanisms of multiple myeloma
- Genetic and Epigenetic mechanisms of multiple myeloma
- The role of blood lipoproteins in the pathogenesis of MM
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.